BioMed Valley Discoveries is participating in both the NCI pediatric and adult MATCH (Molecular Analysis for Therapy Choice) studies.
NCI-MATCH is a precision medicine cancer treatment clinical trial. In this trial, patients are assigned to receive treatment based on the genetic changes found in their tumors through genomic sequencing and other tests.1
To date there are 4 patients enrolled to the ulixertinib arm of the pediatric MATCH trial (APEC1621 – Arm J). The ulixertinib arm of the adult MATCH trial (EAY131 – Arm Z1L) was recently activated and we anticipate patient enrollment to begin soon.